PCV116 COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION—A HORIZONS TRIAL ANALYSIS USING UK VALUATIONS  by Schwenkglenks, M et al.
A334 Paris Abstracts
therapy for primary CVD prevention saves patients money and increases QALYs, but 
at the expense of lost life years.
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COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN 
ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM 
AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP 
REPLACEMENT IN IRELAND
McCullagh L1, Tilson L1, Walsh C2, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, 
Ireland
OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban and dabigatran com-
pared to enoxaparin as venous-thromboembolism prophylaxis post total hip replace-
ment (THR), from the Irish health payer perspective. METHODS: A hybrid model 
combing an acute phase decision tree (180 days post-surgery) and a chronic phase 
Markov model (patient lifetime) was developed using TreeAge Pro 2008®. Outcome 
measures were QALYs and LYGs. Future costs and outcomes were discounted at 4%. 
Treatment efﬁcacy and major bleeding probabilities were derived from pivotal clinical 
trials. Thromboprophylaxis independent probabilities were identiﬁed via a literature 
search. A one-way sensitivity analysis of all probabilities was completed using the 
upper/lower bounds of the 95% conﬁdence interval where available; otherwise point 
estimates were varied o 50%. A probabilistic sensitivity analysis (PSA) using second 
order Monte Carlo simulation was performed. Probabilities were assigned beta distri-
butions. Dirichlet distributions were adopted for multibranch nodes. Utilities and 
direct costs were given beta and lognormal distributions respectively. RESULTS: 
Basecase Analyses: Rivaroxaban dominated both dabigatran and enoxaparin. The 
incremental cost-effectiveness ratios for dabigatran relative to enoxaparin were a1885 
per LYG and a1811 per QALY. One-Way Sensitivity Analysis: The model was robust 
to all but three probability variations; the probabilities that a proximal deep vein 
thrombosis (DVT) will occur on dabigatran, a pulmonary embolism or proximal DVT 
will occur on enoxaparin. PSA: At a a45,000/QALY threshold, the probability that 
rivaroxaban was the most cost-effective strategy was 67%, followed by dabigatran 
(19%) and enoxaparin (14%). A cost-effectiveness plane illustrating scatterplots for 
rivaroxaban versus enoxaparin and dabigatran versus enoxaparin was produced. 
Overlap indicates uncertainty that rivaroxaban is more cost-effective than dabigatran. 
CONCLUSIONS: Basecase analyses indicate that rivaroxaban is more cost-effective 
than enoxaparin or dabigatran. PSA indicates that rivaroxaban is the most cost-
 effective strategy at a a45,000/QALY threshold; however there is uncertainty regard-
ing this strategy being more cost-effective than dabigatran.
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COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN 
EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN 
MAJOR ORTHOPEDIC SURGERY IN POLAND
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OBJECTIVES: To assess clinical effectiveness and cost–effectiveness of fondaparinux 
vs enoxaparin (40 mg or 30 mg twice a day) in extended prophylaxis (administration 
for 30 days) of venous thromboembolism in patients after major orthopedic surgery 
(knee arthroplasty, hip arthroplasty, hip fracture) in Poland. METHODS: Systematic 
review and clinical effectiveness analysis according to Polish HTA Guidelines were 
performed. Only RCTs with high credibility assessment were included in the systematic 
review (according to EBM). Costs valid from public payer’s perspective (National 
Health Fund) were taken into account and were based on data from 2007. Costs of 
pharmacotherapy were estimated with 100% reimbursement (lump sum patient 
payment 3.2 PLN). Both health effects and costs were discounted with ﬁve percent rate 
applied. Analysis was performed within ﬁve percent year time horizon. Sensitivity 
analysis was performed. RESULTS: The analysis showed that prophylaxis with 
fondaparinux was more expensive than treatment of enoxaparin in greater (40 mg) and 
in smaller (30 mg) doses by 211 PLN or 98 PLN respectively; however brought better 
health outcomes by 0.01 LYGs and 0.003 LYGs per patient. ICERs were estimated at 
21,603 PLN and 29,950 PLN, respectively, both below cost-effectiveness threshold in 
Poland (91,000 PLN  3 times GDP per capita). The sensitivity analysis proved that 
costs of pharmacotherapy with fondaparinux and enoxaparin had the biggest impact 
on results. CONCLUSIONS: Extendeding prophylaxis of venous thromboembolism 
with fondaparinux compared with enoxaparin in patients undergoing major orthope-
dic surgery is cost-effective option from public payer’s perspective in Poland.
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DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY 
PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING 
MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS
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OBJECTIVES: Dabigatran etexilate (DBG) is a new oral direct thrombin inhibitor for 
prophylaxis of venous thromboembolism (VTE) in patients who have undergone total 
hip replacement (THR) or total knee replacement (TKR) surgery. Advantages of DBG 
over parenteral prophylaxis might include but are not limited to reduced resource use 
for 1) teaching patients to self-inject; 2) home-care visits for parenteral administration; 
and 3) absence of Heparin Induced Thrombocytopenia (HIT). Based on proven non-
inferiority, the aim of this study was to conduct a cost-minimization analysis of oral 
DBG versus parenteral low-molecular weight heparin (LMWH) and Fondaparinux 
formulations from the perspective of the Dutch National Health Service. METHODS: 
A retrospective cohort study was conducted to measure resource use associated with 
parenteral prophylaxis. Drug-utilization data were combined with local unit costs. 
Probabilistic sensitivity analysis was performed to account for uncertainty around 
relevant parameters included. RESULTS: Home-care visits for parenteral administra-
tion problems were required by 9.9% (95%CI: 6.4–13.4) and 9.6% (95%CI: 5.8–
13.4) of THR and TKR patients, respectively. Based on costs for 1000 patients treated 
with DBG versus LMWHs, per patient cost-savings with DBG were estimated at 
a24.63 (95%CI: 0.56–54.19) and a18.39 (95%CI: 2.54–41.52) for THR and TKR, 
respectively. The probability that DBG would be cost-saving is 97.1% and 95.6% for 
THR and TKR, respectively. These cost-savings were even higher when including 
Fondaparinux with per patient cost-savings of a84.87 (95%CI: 58.04–117.64) and 
a33.41 (95%CI: 12.27–57.36) for THR and TKR, respectively. Separate calculations 
for DBG versus Nadroparin and Dalteparin in THR resulted in a probability of achieving 
cost-savings with DBG of 19.0% and 100%, respectively. For TKR these probabilities 
for DBG versus Nadroparin and Dalteparin were estimated at 37.0% and 100%. 
CONCLUSIONS: Thromboprophylaxis with DBG is cost-saving in patients undergo-
ing THR/TKR for the perspective of the Dutch National Health Service.
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TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN 
ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE 
MYOCARDIAL INFARCTION
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OBJECTIVES: Glycoprotein IIb/IIIa inhibitors are highly effective inhibitors of platelet 
aggregation. The MultiStrategy trial showed Tiroﬁban or Abciximab were similarly 
efﬁcacious in resolving ST-segment elevation at 90 min post intervention following 
Acute Myocardial Infarction. As combination therapy to inhibit platelet function and 
the coagulation cascade to improve cardiovascular outcome is increasingly common 
in Acute coronary settings, the focus is turning to cost efﬁcient approaches. We 
undertook a pharmaco-economic analysis of the MultiStrategy study to identify the 
most cost-efﬁcient therapy. METHODS: Cost-minimization analysis of a randomized 
controlled trial, where costs are calculated only when between group statistical differ-
ences are identiﬁed. Direct medical resources (drugs, procedures, investigations, 
adverse effects and duration of stay) were prospectively collected within the case report 
form. Drug costs were average wholesale prices obtained from the manufacturer. 
RESULTS: Drug utilization and major procedural resources between groups was 
similar; Clopidogrel (p  0.71), Aspirin (p  0.18), Heparin (p  0.14); PCI; stents 
(p  0.81), guidewires (p  0.45), non serious adverse events (p  0.41), Bleeding 
(p  0.775), # Days in hospital (p  0.95). Duration of Tiroﬁban infusion was longer 
19.97h vs. 11.44h (p  0.000) whereas, amount of Glycoprotein inhibitor and number 
of required vials of drug was higher for Abciximab 23,491Mg v. 14,328Mg (p  0.000) 
and 2.933 v. 1.707 (p  0.000) respectively. The average calculated cost of Abciximab 
was higher than Tirﬁban 876.93 vs. a348.20 (p  0.000) or a196,787 total cost dif-
ference between study arms (n  361 patients per arm). CONCLUSIONS: All resource 
variables were similar between arms except for the randomized medication. No 
resource implications of medication side-effects or treatment duration were seen. 
Tiroﬁban is the more cost-efﬁcient Glycoprotein IIb/IIIa inhibitor in achieving ST-
segment resolution at 90min post intervention.
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OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In the HORIZONS randomised controlled trial, anticoagulation with biva-
lirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) was associated with 
similar ischemic event rates and signiﬁcantly reduced bleeding events. Mortality at 30 
days and 1 year, in this indication. We estimated the incremental cost-effectiveness of 
bivalirudin in the HORIZONS trial. UK National Health Service valuations and per-
spective were applied. METHODS: A decision tree model compared the bivalirudin 
and heparin plus GPI strategies investigated in HORIZONS. It was combined with a 
Markov module to achieve a life-long time horizon. The health economic endpoint was 
cost per quality-adjusted life-year (QALY) gained. One-year clinical event rates and 
medical resource use parameters were derived from the HORIZONS dataset. Remain-
ing life expectancy and long-term cardiovascular treatment costs of ﬁrst-year survivors, 
unit costs, and utilities were drawn from published UK sources. Costs and effects were 
discounted at 3.5%. Extensive sensitivity analyses were performed. RESULTS: In 
the base case analysis, the bivalirudin strategy was dominant with an average saving 
of £450 per patient and an average survival gain of 0.09 QALYs per patient. Cumula-
tive costs in the bivalirudin and heparin plus GPI strategies were £12,318 and £12,769 
per patient, respectively. Patients lived 6.05 and 5.96 QALYs. A dominant or highly 
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cost-effective situation was maintained in all sensitivity analyses. In deterministic 
analysis, the results were most sensitive to differences in index hospitalisation length 
of stay between strategies and proportional GPI utilisation (eptiﬁbatide/abciximab). 
In probabilistic analysis, 95.6% of samples (9,557 of 10,000) indicated a dominant 
situation. CONCLUSIONS: The use of bivalirudin instead of heparin plus GPI 
is dominant, i.e. clinically advantageous and cost-saving, in STEMI patients planned 
for PPCI, when UK valuations are applied to the HORIZONS study.
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COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF 
PULMONARY ARTERIAL HYPERTENSION IN FINLAND—A DISCRETE 
EVENT SIMULATION MODELLING
Soini EJ1, Stevenson MD2, Martikainen JA3, Akehurst RL2
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OBJECTIVES: Pulmonary Arterial Hypertension (PAH) is a devastating disease, 
which has a signiﬁcant impact on patients’ quality of life and mortality. Both bosentan 
and inhaled iloprost (INHI) have demonstrated prolonged survival in long-term obser-
vational studies. We assessed the cost-effectiveness of adding bosentan, INHI or no 
active treatment (NAT) to palliative care, for patients with PAH of functional class 
(FC) III in Finland. METHODS: A cost-utility model simulated hypothetical patients 
with PAH, using a lifetime horizon and considering only direct medical costs. Patients 
were assumed to either remain in their FC at 12 weeks until death or to deteriorate 
to FC IV and then receive INHI and palliative care until death. It was assumed that 
the initial choice of treatment would not affect survival, but instead would affect the 
proportion of time spent in FC IV. Deterioration was approximated by time to clinical 
worsening (TTCW), a composite measure of death or worsening of PAH leading to a 
change in treatment. Data on TTCW was taken from published literature and hospital 
databases containing over three years of data for bosentan and from published litera-
ture for palliative care alone. For INHI, the TTCW was favourably assumed to equal 
that for bosentan. The utility associated with each FC taken from published literature; 
non-drug costs were estimated based on published literature and veriﬁed by a Finnish 
expert clinician. Costs and beneﬁts were discounted at 3% per annum. RESULTS: 
Bosentan dominated INHI, providing equivalent QALYs at a reduced cost. Bosentan 
also dominated NAT, providing an additional 0.38 QALYs whilst saving a8.142. 
Probabilistic sensitivity analyses estimated the probabilities of bosentan being cost-
effective compared with NAT as 79% and 86% at cost per QALY thresholds of 
a30,000 and a50,000 respectively. CONCLUSIONS: Bosentan is a more cost-effective 
ﬁrst-line therapy for patients with PAH FC III in Finland than either INHI or NAT.
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ECONOMIC EVALUATION OF INHALED ILOPROST IN PRIMARY 
PULMONARY HYPERTENSION IN THE UK
Ashley D1, Lloyd AC2, Gilmour L1
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OBJECTIVES: Primary Pulmonary Hypertension (PPH) is a rare, progressive degen-
erative disorder resulting in deteriorating functional status, poor quality of life and 
ultimately death. Inhaled iloprost is indicated for the treatment of patients with PPH 
at New York Heart Association (NYHA) functional class III. This study used an eco-
nomic model to evaluate the cost-effectiveness of inhaled iloprost compared to current 
standard treatment in PPH. METHODS: A Markov model was used to allocate 
patients to states according to NYHA functional classiﬁcation and treatment received. 
Patients enter the model when oral therapies have failed or not been tolerated and can 
improve NYHA classiﬁcation, remain stable, deteriorate or die. The model compares 
i) inhaled iloprost until patients reach NYHA IV; then, intravenous epoprostenol with 
ii) immediate epoprostenol. Efﬁcacy was taken from 12 week placebo controlled 
studies of each agent; quality of life from EQ-5D data collected in the study of iloprost. 
Costs were estimated at 2008 prices from the perspective of the NHS. The time horizon 
of the economic analysis is from failure of oral therapy until death; the primary 
outcome is cost per QALY gained. RESULTS: The model estimated that treating with 
inhaled iloprost will reduce lifetime cost by £348,000 (95% CI: £223,000, £529,000) 
and increase QALYs by 0.04 (0.92, 0.51) per person treated. The model is sensitive 
to the cost of the drugs used, but less sensitive to the other costs of managing PPH, 
utility inputs or the sources of efﬁcacy and safety inputs chosen. CONCLUSIONS: 
Using inhaled iloprost before epoprostenol offers substantial savings compared to 
immediate epoprostenol, with no signiﬁcant impact on health outcomes. The strategy          
of reserving intravenous therapy for patients unable to tolerate less expensive and 
invasive therapies would be economically attractive.
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COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY 
SYNDROME PATIENTS IN THE NETHERLANDS
Thurston SJ1, Webb K2, Ong S2, Meerding WJ3, van Hout BA1
1Pharmerit Ltd, York, North Yorkshire, UK, 2Pﬁzer Ltd, Tadworth, Surrey, UK, 3Pﬁzer bv, 
Capelle a/d IJssel, The Netherlands
OBJECTIVES: To estimate the long- and short-term costs and effects of 2 year treat-
ment with high-dose atorvastatin versus high and standard dose simvastatin in patients 
with acute coronary syndrome (ACS). METHODS: Efﬁcacy is estimated based on a 
Bayesian meta-analysis linking decrease in LDL cholesterol levels to decreases in sec-
ondary cardiac events (MIs, strokes, cardiovascular deaths) drawing data from statin 
trials in ACS (AtoZ, MIRACL, PROVE-IT) and using priors from published statin 
meta analyses (CTT, Law). A Markov model combines estimates of the occurrence of 
later events; Dutch cost data; and quality of life. Risks are taken from the ACS CURE 
study. RESULTS: Analyses are conducted using a baseline event risk during the ﬁrst 
6 months of 12.1% and of 3.89% during later months. A base case analysis of atorv-
astatin 80 mg versus simvastatin 80 mg is chosen to align with clinical trial evidence 
used in the Bayesian analysis. This resulted in a cost per QALY of a29,000 and a 
number needed to treat to avoid one event (NNT) estimate of 80. The comparison of 
atorvastatin 80 mg and simvastatin 40 mg resulted in a NNT of approximately 58 
and a cost per QALY estimate of a21,000, based on the assumption that atorvastatin 
80 mg has an 18% greater efﬁcacy in terms of LDL-C reduction. ICERs improve when 
risk with age is reduced, lower discount rates are used, and when atorvastatin cost is 
decreased. CONCLUSIONS: Based on preliminary ﬁndings, the probability that high-
dose atorvastatin has a cost effectiveness ratio under a30,000 is estimated at 67.3% 
when compared to simvastatin 40 mg and at 56.9% when compared with 80 mg of 
simvastatin. Univariate sensitivity analyses show that changes in the costs of atorvas-
tatin, and the risk of having events have the biggest impact on the results.
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DRONEDARONE IN ATRIAL FIBRILLATION: MODELING  
HEALTH OUTCOMES
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OBJECTIVES: Dronedarone is a new multichannel-blocking antiarrhythmic drug. In 
ATHENA, dronedarone (400 mg bid), reduced cardiovascular hospitalizations or 
death by 24% (p  0.0001) versus standard of care (SOC) alone. Our objective was 
to predict the long-term health effects in terms of survival and quality-adjusted survival 
comparing dronedarone on top of SOC versus SOC alone, amiodarone or sotalol. 
METHODS: A state transition model (evaluated using 1st order Monte Carlo simula-
tion) was developed. When treated with dronedarone or SOC, the risk of suffering 
symptomatic AF, stroke, acute coronary syndromes (ACS), congestive heart failure or 
cardiovascular death, or discontinuing treatment was estimated using survival analysis 
based on the ATHENA patient level data (n  4,628). Death from non-cardiovascular 
causes or following stroke or CHF was based on UK national statistics and literature 
data. Patients treated with amiodarone or sotalol had the risk of events modiﬁed with 
relative risks based on a mixed treatment comparison. When discontinuing dronedar-
one or rhythm control therapy, patients were assumed to receive SOC alone and thus 
have the same transition probabilities as in the SOC arm. Outcomes were discounted 
at 3.5% per annum. RESULTS: Assuming lifetime treatment, the predicted survival 
with dronedarone was 9.01. The corresponding number of QALYs was 6.97. With 
amiodarone, the model predicts an expected survival of 7.14 years (5.52 QALYs). For 
sotalol the corresponding numbers were 5.83 years and 4.53 QALYs. CONCLU-
SIONS: Dronedarone demonstrated longer predicted survival compared to SOC alone, 
amiodarone and sotalol. This beneﬁt is sustained when adjusted by quality of life, and 
is comparable with survival gains from established interventions in cardiology.
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ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC STROKE IN THE 
NETHERLANDS. A COST-UTILITY ANALYSIS
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OBJECTIVES: Preliminary evidence indicates that intra-arterial (IA) thrombolysis is 
a more effective treatment for a subgroup of ischemic stroke patients who have a 
visible intracranial occlusion than intravenous (IV) thrombolysis. This cost-utility 
analysis compares four treatment strategies for ischemic stroke: conservative treat-
ment, IV thrombolysis, IA thrombolysis and a bridging strategy of both IV and IA 
thrombolysis (with or without mechanical thrombectomy). METHODS: A health 
economic model was developed that compared the four different treatments. A deci-
sion tree with a Markov model was used to assess 6 months- and lifetime costs (in 
Euros) and effects (in QALYs) of these different treatment strategies. A literature 
search provided the estimates used in the decision tree and data from the EDISSE trial 
was used for cost estimates, combined with cost estimates from Erasmus MC Univer-
sity Hospital Rotterdam on IA thrombolysis. Current Dutch epidemiological informa-
tion was used in the Markov model to calculate lifetime costs and effects for all 
treatment strategies. RESULTS: From a lifetime perspective, IV thrombolysis is the 
dominant treatment strategy: it saves a1717 per QALY gained compared to the con-
servative treatment. The bridging strategy costs an additional a7217 per QALY gained 
compared to IV thrombolysis. IA thrombolysis is dominated by the other strategies 
as it gains equal QALYs as IV thrombolysis while it is a slightly more expensive treat-
ment. A probabilistic sensitivity analysis shows that depending on the willingness to 
pay, these treatment strategies are cost-effective at six months in 84 percent of cases. 
CONCLUSIONS: The bridging strategy signiﬁcantly improves functional outcome of 
acute ischemic stroke patients at reasonable additional costs. However, more empirical 
studies need to be performed in order to reduce the considerable amount of uncertainty 
concerning the costs and effects of IA thrombolysis for acute ischemic stroke.
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OBJECTIVES: The aim of our study was to compare the costs and cost drivers of 
contrast-enhanced magnetic resonance angiography (MRA) and digital subtraction 
